Peptide therapeutics market seen topping $222B by 2030

The Business Research Company projects the global peptide therapeutics market will pass $222 billion in 2030, driven by demand for obesity and diabetes treatments, regulatory approvals and GLP-1 research. North America and the U.S. are expected to lead the market, while branded therapies remain the largest segment.

Why it matters: - Peptide therapeutics are moving from a niche category into a major pharmaceutical market, with projected 2030 revenue of more than $222 billion. - The forecast points to growing demand for targeted treatments in obesity, diabetes, cancer and other chronic diseases. - The market is expected to account for nearly 9% of the broader pharmaceuticals industry, which is projected to reach $2,496 billion by 2030.

What happened: - The Business Research Company released its Peptide Therapeutics Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report says the peptide therapeutics market is expected to surpass $222 billion in 2030. - The market is projected to grow at a 10% CAGR leading up to 2030. - North America is forecast to be the largest region in 2030, with a market value of $95 billion. - The U.S. is expected to be the largest country in the market in 2030, valued at $85 billion.

The details: - North America is projected to grow from $64 billion in 2025 to $95 billion in 2030, at an 8% CAGR. - U.S. market value is projected to rise from $58 billion in 2025 to $85 billion in 2030, also at an 8% CAGR. - The branded segment is expected to be the largest type category, reaching $198 billion and representing 89% of the market in 2030. - The generic and branded segments together are projected to add more than $86 billion in market value by 2030. - The branded market is projected to grow by $78 billion from 2025 to 2030. - The generic market is projected to grow by $8 billion over the same period. - The market is segmented by route of administration into parenteral, mucosal, oral and transdermal. - The market is segmented by application into cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly and other applications. - The report identifies rising obesity and diabetes prevalence, expanding regulatory approvals, and increased GLP-1 research spending as key demand drivers. - The report says obesity and diabetes trends are expected to contribute about 1.0% annual growth to the market. - Expanding regulatory approvals and product innovations are projected to contribute around 1.0% annual growth. - Increasing investment in GLP-1 and peptide drug research is projected to contribute about 0.5% annual growth. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The forecast suggests peptide drugs are benefiting from a broader shift toward targeted biologic therapies and precision medicine. - The strongest near-term opportunity appears to be in branded products, where proprietary formulations and patent-protected innovation can support higher market value. - The report’s growth assumptions highlight a market shaped by clinical demand and pipeline expansion, not just volume growth.

What's next: - The report expects continued commercialization of peptide medicines across chronic disease categories. - Further regulatory approvals and product launches could keep expanding the addressable market through 2030. - More investment in peptide engineering and GLP-1 development is likely to shape the next wave of competition.

The bottom line: - Peptide therapeutics are on track to become a much larger slice of pharma, with North America, the U.S. and branded drugs leading the next phase of growth.